SequelSEC

Dogwood Therapeutics, Inc. DWTX

Pharmaceutical Preparations · CIK 0001818844 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$27.97M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Dogwood Therapeutics, Inc. (DWTX) reported net income of -$34.26M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Dogwood Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Dogwood Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$27.97M-$12.23M-$5.45M-$12.32M-$15.64M-$10.01M
Net income-$34.26M-$12.35M-$5.30M-$12.25M-$15.96M-$10.35M
Research & development$21.87M$3.53M$1.73M$8.07M$10.80M$194.01K
Weighted-average diluted sharesshares 4.98Mshares 1.03MUnavailableshares 11.07Mshares 8.33Mshares 4.93M
Pretax income-$34.04M-$12.35M-$5.30M-$12.25M-$15.96M-$10.35M
Income tax expense$221.10K-$503UnavailableUnavailableUnavailableUnavailable
Diluted EPS$-7.13$-12.52$-7.05$-1.11$-1.92$-2.10
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$6.10M$8.70M$3.72M$4.25M$4.85M$9.81M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Dogwood Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$6.52M$14.85M$3.32M$7.03M$14.01M$29.80M
Total assets$90.17M$94.31M$4.17M$8.37M$15.78M$31.47M
Current assets$8.43M$16.54M$4.17M$8.37M$15.78M$31.47M
Total liabilities$15.27M$30.03M$358.55K$1.04M$1.28M$1.53M
Current liabilities$3.06M$3.18M$358.55K$1.04M$1.28M$1.53M
Total equity incl. NCI$74.90M-$10.12M$3.81M$7.33M$14.50M$29.94M
Temporary (mezzanine) equityUnavailable$74.41MUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$12.40M$11.81MUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$760.94K$1.23M$111.91K$573.16K$353.86K$368.90K

Cash flow

Dogwood Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$15.62M-$8.79M-$4.87M-$11.47M-$15.69M-$3.90M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailable$3.76MUnavailableUnavailableUnavailableUnavailable
Financing cash flow$7.28M$16.70M$1.16M$4.49M-$97.60K$33.38M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$355.64K$476.02K$619.97K$582.66K$322.88K$7.43M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Dogwood Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.76x5.21x11.62x8.02x12.37x20.55x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DWTX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-18View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.